Yahoo Finance Live anchors discuss stock performance for cruise lines.
Leaving these accounts open could tarnish your golden years.
In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.
In this article, we will look at 5 high-yielding dividend stocks to buy according to journalist investor Jim Cramer. If you want to explore similar stocks, you can also take a look at Jim Cramer is Recommending These 2 High-Yield Dividend Stocks. The Short-Term Camp Vs The Silent Majority Following the Fed’s 75 basis point […]
Meta Platforms is not doing well. The social-media giant, parent of Facebook, Instagram and WhatsApp, has been sending alarming signals for several months. It was ejected from the world's top 10 most valuable companies, and this year its market capitalization has fallen by nearly $545 billion.
Yahoo Finance's Josh Schafer discusses Wall Street analyst calls on Nike after the athletic apparel giant reported some red flags in its earnings results.
Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. ET Friday morning. The biotech's stock appears to be getting a boost from both a broad upward trend across the biotechnology space today, as well as from rumors circulating on social media about a possible buyout. Bluebird scored two approvals from the Food and Drug Administration (FDA) earlier this year for its one-and-done gene therapies: Skysona for cerebral adrenoleukodystrophy (CALD) and Zynteglo for transfusion-dependent beta-thalassemia (TDT).
Both Stanley Black & Decker (NYSE: SWK) and 3M (NYSE: MMM) are Dividend Kings that have experienced a torrid 2022, with the former down 57% and the latter down 36%. Stanley Black & Decker's management started the year expecting a gradual easing of supply chain pressures and raw-material costs. Unfortunately, the supply chain pressures have proved unrelenting.For example,management started the year expecting $800 million in cost inflation, only to upgrade that figure to $1.4 billion in late April.
Inflation, interest rates, and recession – these are the bogeymen of investing, and they’ve been watching over our shoulders for the past several months. We all know the story by now, the rate of inflation is running at generational highs, the Federal Reserve is hiking rates in an attempt to push back against high prices, and that’s likely to tip the economy into recession. At a time like this, investors are showing a growing interest in finding strong defensive portfolio moves. It’s a mindset t
New research based on the life-cycle model says that people should strive for a consistent standard of living through their lives.
With the S&P 500 index making new lows in 2022, it is crucial investors stay the course and continue adding high-quality businesses to their portfolios -- through dollar-cost averaging, if possible. Shopify (NYSE: SHOP) is currently light on profits yet is vital to the burgeoning U.S. e-commerce industry. Adyen (OTC: ADYE.Y) and InMode (NASDAQ: INMD) offer the beautiful pairing of high sales growth and strong free cash flow (FCF) creation and profitability.
Nvidia (NASDAQ: NVDA) has been a top performer on the stock market over the years, with shares of the graphics card specialist rising more than 3,600% over the past decade. The broader market correction has sent shares of Nvidia packing, with the tech giant losing more than 60% of its value since December 2021. The sell-off has brought Nvidia's market capitalization down to just over $300 billion from more than $800 billion in December last year.
Billionaire investor Stanley Druckenmiller sees a “hard landing” by the end of 2023 as the Federal Reserve’s aggressive monetary tightening will tip the U.S. economy into recession.
Tesla CEO Elon Musk’s text messages, made public Thursday in his legal dispute with Twitter (TWTR), show he communicated about its fake account issues both before and after agreeing to buy it for $44 billion.
AT&T is trading lower Thursday and is very close to a major support breakdown. How major do you ask? Let's look at one Point and Figure chart. In the daily Point and Figure chart of T, below, we used close-only price data.
Shares of Carnival (NYSE: CCL), the world's biggest cruise line operator, were tumbling today after the company badly missed estimates in its third-quarter earnings report. Carnival continued to rebound from the pandemic in the third quarter, but its results fell short of expectations and it reported a significant loss. Revenue jumped nearly 80% sequentially from the second quarter to $4.31 billion, but that still missed analysts' consensus estimate of $5.07 billion.
Yahoo Finance Live’s Brian Sozzi joins the Live show to discuss a Raymond James analyst’s Outperform rating on Microsoft.
(Bloomberg) -- Mohamed El-Erian has a cautionary word for anyone anticipating an end to interest-rate increases from the Federal Reserve and other central banks.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandTop Apple Executive Is Leaving After Making Crude Remarks in TikTok VideoMeta to Cut Headcount for First Time, Slash Budgets Across TeamsMarjorie Taylor Greene’s Husband Files for Divorce After 27 YearsPutin Says Annexation Is Forever, Defends Ukraine L
David “Sandy” Gottesman, a Berkshire Hathaway board member, billionaire and longtime friend of Warren Buffett, died Wednesday at 96. In 1964, Gottesman founded the New York investment firm First Manhattan, which announced his death on its website. Gottesman befriended Buffett around the time that Buffett took control of Berkshire (ticker: BRK.A) in 1965 and was an early investor in the company when its stock sold for a tiny fraction of its current price.
Carnival's (CCL) third-quarter fiscal 2022 performance reflects solid booking trends owing to relaxed protocols and better alignment of land-based vacation alternatives.